Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Rangit Vallapureddy"'
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 2, Pp s41-s41 (2022)
Background: Vaccination against COVID-19 has demonstrated high efficacy in preventing illness severe enough to result in hospitalization. Despite these data, universal vaccine adoption by different population groups, including hospital employees, has
Externí odkaz:
https://doaj.org/article/991f5f0f34a74800bc36d405abbedbb4
Autor:
Justin M. Watts, Angela J. Fought, Shradha Patel, Ayalew Tefferi, Dalissa Tejera, Naseema Gangat, Roberto Tapia, Raajit K. Rampal, Jessica K. Altman, Noushin Farnoud, Amy Handlogten, Akshar Patel, Kristen Englund Prahl, Rangit Vallapureddy, Alfred Rademaker, Juehua Gao, Amber Thomassen, Christian Marinaccio, Ronan Swords, Brady L. Stein, Qiang Jeremy Wen, Stephanie Barath, Aref Al-Kali, Juan Carlos Nobrega, Olga Frankfurt, Francis J. Giles, John D. Crispino, Peng Ji, Darci Zblewski, Christopher Famulare, Mrinal M. Patnaik, Sandeep Gurbuxani, Yvonne Trang Dinh, Amy Graf
Publikováno v:
Clinical Cancer Research. 25:4898-4906
Purpose: Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic complications, and a risk of evolution to acute leukemia. The JAK kinase inhibitor ruxolitinib
Autor:
Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi, Maura Nicolosi, Naseema Gangat, Rangit Vallapureddy, Rhett P. Ketterling, Domenico Penna
Publikováno v:
Leukemia. 33:2522-2553
Autor:
Mrinal M. Patnaik, Curtis A. Hanson, Rangit Vallapureddy, Christy Finke, Ayalew Tefferi, Animesh Pardanani, Naseema Gangat, Rhett P. Ketterling, Amy Phelps, Terra L. Lasho
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-4 (2019)
Blood Cancer Journal
Blood Cancer Journal
Autor:
Curtis A. Hanson, Ayalew Tefferi, Christy Finke, Terra L. Lasho, Domenico Penna, Animesh Pardanani, Rangit Vallapureddy, Naseema Gangat, Rhett P. Ketterling
Publikováno v:
American Journal of Hematology. 94:286-290
In the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (
Autor:
Ayalew Tefferi, Curtis A. Hanson, Terra L. Lasho, Naseema Gangat, Katherine P. Hoversten, Mrinal M. Patnaik, Christy Finke, Rangit Vallapureddy, Rhett P. Ketterling
Publikováno v:
Leukemia & Lymphoma. 59:2998-3001
Chronic myelomonocytic leukemia (CMML) is an aggressive hematological malignancy with overlapping myeloproliferative and myelodysplastic features and an inherent risk for leukemic transformation [1...
Autor:
Ayalew Tefferi, Mrinal M. Patnaik, Rangit Vallapureddy, Christy Finke, Naseema Gangat, Terra L. Lasho, Rhett P. Ketterling, Abhishek A. Mangaonkar
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 3, Pp 1-4 (2018)
Blood Cancer Journal
Blood Cancer Journal
Autor:
Katherine P. Hoversten, Terra L. Lasho, Christy Finke, Ayalew Tefferi, Rhett P. Ketterling, Rangit Vallapureddy, Mrinal M. Patnaik, Naseema Gangat, Curtis A. Hanson
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 1, Pp 1-5 (2018)
Blood Cancer Journal
Blood Cancer Journal
Autor:
Naseema Gangat, Ayalew Tefferi, Aref Al-Kali, Fevzi Firat Yalniz, Rhett P. Ketterling, Rangit Vallapureddy, Christy Finke, Terra L. Lasho, Curtis A. Hanson, Mrinal M. Patnaik
Publikováno v:
American Journal of Hematology. 93:65-73
Therapy related myeloid neoplasms (t-MN) including therapy related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML) are associated with aggressive disease biologies and poor outcomes. In this large (n = 497) and informative (inclu
Autor:
Mrinal M. Patnaik, Ayalew Tefferi, Terra L. Lasho, Animesh Pardanani, Ryan M. Carr, Naseema Gangat, Mark R. Litzow, Aref Al-Kali, Christy Finke, Abhishek A. Mangaonkar, Rangit Vallapureddy, Moritz Binder, Rhett P. Ketterling, Tucker W. Coston, Prateek Pophali, Darci Zblewski
Publikováno v:
American Journal of Hematology.
Hypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group)